Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis
Changhoon Yoo(Ulsan College), Song Cheol Kim(Ulsan College), Ki Byung Song(Ulsan College), Myung‐Hwan Kim(Korea Aerospace Research Institute), Hyung‐seung Jin(Ulsan College), Dae Wook Hwang(Asan Medical Center), Sung Koo Lee(Ulsan College), Kyu‐pyo Kim(Ulsan College), Dong Wan Seo(Dankook University), Baek‐Yeol Ryoo(Asan Medical Center), Seung Soo Lee(Asan Medical Center), Jaewon Hyung(Ulsan College), Tae Jun Song, Jae Hoon Lee(Ulsan College), Jin Hee Kim(University of Ulsan), Sang Soo Lee(Chungbuk National University Hospital), Jin‐hong Park, Jae Ho Jeong(Ulsan College), Woohyung Lee(Ulsan College), Heung-Moon Chang(Asan Medical Center), Do Hyun Park(Massachusetts Institute of Technology)
Cited by 38
Related Papers
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
|Proceedings of the National Academy of Sciences|2017|577
TIMP-2 Mediated Inhibition of Angiogenesis
|Cell|2003|510
A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts
|Gastroenterology|2015|472